Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Racial and Gender Disparities in Psoriatic Arthritis
Description
The presentation discusses racial and gender disparities in psoriatic arthritis (PsA), highlighting the importance of recognizing these differences in treatment approaches. It begins by engaging the audience in a reflection on the demographics of patients they typically consider, revealing a bias towards Caucasian representations. Racial minorities experience lower diagnosis rates and greater diagnostic delays due to factors such as implicit biases and lack of access to healthcare. The speaker emphasizes that Black and Hispanic individuals often face underdiagnosis and treatment disparities, receiving fewer biologics compared to white patients. Additionally, the prevalence and presentation of symptoms can vary significantly across racial groups.
Gender disparities are also addressed, with women often being diagnosed later than men and reporting higher pain levels without corresponding radiographic damage. Women with PsA tend to have more fatigue, comorbidities like obesity and depression, and receive lower prescriptions for biologics compared to men, despite higher symptom burden. The speaker calls for increased diversity in clinical trials to ensure findings are applicable to all demographics and mentions the necessity of addressing biases within the medical community. Overall, the presentation advocates for improved awareness, provider education, equitable healthcare access, and more inclusive research to promote fair treatment and better outcomes for all PsA patients.
Conclusions
- Racial and gender disparities exist in the diagnosis, severity, and treatment of psoriatic arthritis (PsA).
- Black and Hispanic patients are often underdiagnosed or diagnosed later than White patients, largely due to healthcare access barriers and implicit biases among physicians.
- Women with PsA experience higher rates of fatigue and pain despite having less radiographic damage than men, leading to a lower quality of life.
- Despite similar symptom burdens, women receive lower prescription rates for biologics compared to men, which may be due to biases in treatment.
- Access to biologic treatments is significantly lower in racial minorities, with Black patients having 40% lower odds of receiving biologics compared to White patients.
- Clinical trials for PsA often underrepresent minorities and women, leading to limited generalizability of treatment findings.
- It is important to increase diversity in clinical trials, improve healthcare access, and provide education to address implicit biases in diagnosis and treatment.
- Future research should focus on understanding the genetic and environmental factors influencing PsA in diverse populations and ensuring all patients have equitable access to the latest treatments.
- Helliwell PS et al. 'Gender Differences in Psoriatic Arthritis: A Systematic Review.' Arthritis Rheumatol, 2019
- Eder L et al. 'Clinical Features of Psoriatic Arthritis by Gender.' Arthritis Res Ther, 2021
- Tillett W et al. 'Gender Differences in Pain and HRQoL in PsA.' Rheumatology (Oxford), 2018
- Mease PJ et al. 'Gender Bias in PsA Clinical Trials.' Arthritis Care Res, 2022
- Ogdie A et al. 'Disparities in PsA Diagnosis and Treatment.' Arthritis Care Res, 2017
- Wan J et al. 'Racial Disparities in Biologic Treatment of PsA.' JAMA Dermatology, 2020
- Takeshita J et al. 'PsA Outcomes in Racial and Ethnic Minorities.' JAMA Dermatology, 2019
- Shah N et al. 'Minority Representation in PsA Clinical Trials.' Rheumatology, 2022
- Lubrano E, Scriffignano S, Fatica M, et al. Psoriatic arthritis in males and females: differences and similarities. Rheumatol Ther. 2023;10(3):589-599